10-Q: Odysight.ai Q2 Loss Widens Amid Strategic Shifts

Odysight.ai reported a widened net loss in Q2 2025 despite a significant capital raise and increased R&D, driven by a major customer's halted orders and rising operational costs.

Summary

• Net loss for the six months ended June 30, 2025, increased to $8.34 million, up 56% from $5.34 million in the same period of 2024.
• Operating loss for the six months ended June 30, 2025, widened to $8.998 million, a 57% increase from $5.728 million in the prior year period.
• Revenues for the six months ended June 30, 2025, increased by 77% to $2.427 million from $1.368 million, primarily due to the derecognition of a $1.69 million contract liability related to a Fortune 500 medical company customer.
• Revenues for the three months ended June 30, 2025, decreased significantly by 69% to $362 thousand from $1.181 million in the same quarter of 2024, mainly due to the absence of new purchase orders from the Fortune 500 medical company customer.
• Gross profit for the six months ended June 30, 2025, increased by 131% to $671 thousand, while for the three months ended June 30, 2025, it decreased by 74% to $133 thousand.
• Research and development expenses increased by 63% to $4.843 million for the six months ended June 30, 2025, reflecting new product development and increased personnel.
• Sales and marketing expenses surged by 123% to $1.024 million for the six months ended June 30, 2025, driven by efforts to penetrate new markets.
• General and administrative expenses rose by 47% to $3.802 million for the six months ended June 30, 2025, due to increased payroll, executive bonuses, and costs associated with the Nasdaq uplisting and fundraising.
• Cash and cash equivalents and restricted cash stood at $33.2 million as of June 30, 2025, up from $18.164 million at December 31, 2024, primarily due to a public offering.
• The company completed a public offering in February 2025, raising approximately $20.9 million in net proceeds.
• Backlog as of June 30, 2025, was approximately $14.4 million, a slight decrease from $15.0 million at December 31, 2024.
• Accumulated deficit reached $54.3 million as of June 30, 2025.

Sentiment

Score: 4

Explanation: The company reported significantly widened losses and a substantial Q2 revenue decline due to the loss of a major customer's orders. While a recent capital raise provides a strong cash position, the underlying operational performance and continued unprofitability indicate significant challenges and uncertainty.

Positives

• Successfully completed a public offering in February 2025, raising approximately $20.9 million in net proceeds, significantly bolstering cash reserves to $33.2 million.
• Common stock began trading on the Nasdaq Capital Market under the symbol ODYS on February 11, 2025, enhancing market visibility and access to capital.
• Experienced growing interest in technology from Israeli clients, including government agencies and R&D programs, potentially leading to more rapid assimilation of technology into relevant platforms.
• Gross profit for the six months ended June 30, 2025, increased by 131% to $671 thousand, although this was influenced by accounting derecognition.

Negatives

• Net loss widened by 56% to $8.34 million for the six months ended June 30, 2025, compared to the prior year period.
• Operating loss increased by 57% to $8.998 million for the six months ended June 30, 2025.
• Revenue for the three months ended June 30, 2025, decreased substantially by 69% to $362 thousand, primarily due to the absence of a purchase order from a major Fortune 500 medical company customer for 2025.
• Full derecognition of contract fulfillment assets ($1.017 million) and a significant portion of contract liabilities ($1.796 million) related to the medical company customer, indicating a halt in that business relationship.
• Recognized an inventory impairment of $203 thousand related to the medical company customer.
• Significant increases in operating expenses: R&D up 63%, Sales and Marketing up 123%, and G&A up 47% for the six months ended June 30, 2025.
• Accumulated deficit increased to $54.3 million as of June 30, 2025, indicating continued unprofitability.

Risks

• The ongoing war in Israel, including direct conflict with Iran in June 2025, poses risks of political, economic, and military instability, leading to minor operational disruptions, temporary office closures, and employees being called to military reserve duty.
• Dependence on a limited number of customers for a substantial portion of revenue, as evidenced by the loss of purchase orders from a major Fortune 500 medical company customer.
• Need for additional funding to support ongoing research and development, scale-up of solutions, and commercialization efforts, with no assurance of obtaining capital on acceptable terms or at all.
• U.S. trade tariffs implemented in 2025 may increase costs of importing products and supply chain costs, potentially reducing profit margins and affecting competitive position.
• Uncertainty and volatility introduced by tariffs complicate decision-making, planning, and forecasting.
• Risk of product liability claims or product recalls.
• Impact of competition and new technologies in the vision-based sensor market.
• Security, political, and economic instability in the Middle East could harm business operations.

Future Outlook

Management expects to continue incurring significant research and development and other costs, requiring additional funding to achieve profitability. The company anticipates being unprofitable for the foreseeable future. Expenses are expected to increase with ongoing R&D, scaling up of Odysight TruVision solutions, and commercialization efforts. Future capital raises may occur through equity or debt financing, potentially leading to further dilution.

Management Comments

• Management believes existing cash and cash resources will allow the company to fund its operating plan through at least the next 12 months from the filing date.
• The company does not expect a substantial impact on its operations from the war in Israel, despite minor disruptions and temporary office closures.
• The increase in revenue for the six-month period was primarily due to the full derecognition of the contract liability associated with the Fortune 500 medical company customer, and to an increase in revenues from vision-based platform solutions for PdM and CBM.
• The increase in research and development expenses was mainly due to the development of new products and the resulting increase in payroll and related expenses related to the recruitment of new employees, an increase in stock-based compensation from new option grants and procuring materials and services of subcontractors for Industry 4.0 projects.
• The increase in sales and marketing expenses was primarily driven by efforts to penetrate new markets and enhance product visibility, leading to higher payroll, stock-based compensation, and engagement of new marketing consultants and participation in exhibitions.
• The increase in general and administrative expenses was primarily due to an increase in payroll and related expenses due to the recruitment of new employees, including a CFO, and cash compensation bonuses paid to senior executives, expenses related to fundraising and uplisting to Nasdaq, and an increase in stock-based compensation from new option grants.

Industry Context

Odysight.ai operates in the growing Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets, leveraging vision-based AI solutions. The company's technology is applied across aerospace, Industry 4.0, transportation, and energy sectors, with historical revenue from the medical sector. The shift in focus towards defense and Industry 4.0 is evident, aligning with broader trends of integrating advanced technologies for efficiency and safety in industrial processes.

Comparison to Industry Standards

• Odysight TruVision solution was successfully used by NASA, including a repeat order, indicating strong validation within the aerospace sector.
• Customers include the Israeli Air Force, Israeli Ministry of Defense, and France-based Safran Aircraft Engines, demonstrating adoption by significant defense and aviation entities.
• The company previously had a substantial revenue stream from a leading Fortune 500 medical company, showcasing its capability in the medical device sector, though this relationship has recently changed.
• The company's solutions are deployed in hard-to-reach locations and harsh environments, a critical capability for industrial and defense applications, comparable to specialized monitoring systems used by global defense contractors.

Management Changes

Corporate Governance

Legal Proceedings

• No claims or actions are currently pending against the company that management believes could have a material adverse effect on results of operations, financial condition, or cash flows.

Related Party Transactions

• Moshe (Mori) Arkin, a major stockholder and director, participated in the March 2021 private placement and the July 2024 private placement.
• The Phoenix Insurance Company Ltd. and Shotfut Menayot Israel Phoenix Amitim (Phoenix Holdings) participated in the March 2023 and July 2024 private placements.
• Jackson Schneider, a director, entered into a revised Director Appointment and Service Agreement on August 13, 2025, detailing his compensation, stock options, and a commission structure for new commercial agreements.

Stakeholder Impact

• Shareholders: Experienced dilution from the recent public offering, and face potential future dilution from additional capital raises. The widened losses and customer shift may impact share price volatility.
• Employees: Some executives and employees, including the CEO, have been called to military reserve duty due to the war in Israel, causing minor disruptions. The company is actively recruiting new employees, particularly in R&D and sales.
• Customers: Some clients and potential clients have delayed finalizing purchase orders due to the war in Israel. The company is shifting focus from a major medical customer to defense and Industry 4.0 clients.
• Suppliers: Potential for increased supply chain costs due to U.S. trade tariffs on imported products and components, which could affect the company's profit margins.

Next Steps

• Continue to invest in research and development for new products and additional functionality.
• Scale up Odysight TruVision solutions.
• Incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution.
• Recruit additional research and development employees, with increased focus on R&D activities in the Industry 4.0 domain.
• Expand selling and marketing efforts in the Industry 4.0 domain.
• Potentially acquire complementary businesses.
• Continue to incur additional costs associated with operating as a public company.

Key Dates

Recommendation

The company's financial performance shows significant widening of losses and a substantial Q2 revenue decline, primarily due to the cessation of orders from a major medical customer. This indicates operational challenges and a need for strategic re-alignment. However, the recent public offering has significantly strengthened the cash position, providing a crucial liquidity buffer for at least the next 12 months. The company's technology is validated by high-profile clients like NASA and major defense contractors, and there's growing interest from Israeli defense clients. The strategic shift towards Industry 4.0 and defense markets, while costly in the short term, could offer long-term growth potential. Given the current unprofitability and the uncertainty surrounding the transition and market penetration, a 'hold' recommendation is appropriate. Investors should monitor the success of new market penetration, cost management, and progress towards profitability.

Keywords

Predictive Maintenance, Vision-based AI, Condition Based Monitoring, Aerospace, Defense, Industry 4.0, Medical Devices, Sensor Technology, SEC Filing, Quarterly Report, Financial Results, ODYS